SAdd image
Survodutide
Weight LossSingleA dual GLP-1 / glucagon receptor agonist in clinical development, similar mechanism to mazdutide.
Half-life
144 h
Common dose
300 – 6000 mcg
Dosing frequency
Weekly
Administration
Subcutaneous
How it works
Survodutide engages both GLP-1 and glucagon receptors, driving combined appetite suppression and increased basal metabolic rate.
Protocol notes
Trial titration starts low (~0.3 mg weekly) and increases over weeks up to ~6 mg weekly.
Reported side effects
Standard GLP-1-class GI effects.